首页> 外文OA文献 >European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer

【2h】

European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer

机译：欧洲癌症研究与治疗组织（EORTC）08957拓扑替康联合顺铂作为难治性和敏感性小细胞肺癌的二线治疗的II期研究

页面导航

著录项
相似文献
相关主题

著录项

作者
Ardizzoni, A.; Manegold, C.; Debruyne, C.; Gaafar, R.; Buchholz, E.; Smit, E. F.; Lianes, P.; ten Velde, G.; Bosquee, Léon; Legrand, Catherine; Neumaier, C.; King, K.; Giaccone, G.;
展开▼
作者单位

展开▼
年度 2003
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and N [J] . Ardizzoni A, Hansen H, Dombernowsky P, Journal of Clinical Oncology . 1997,第5期

机译：拓扑替康，一种用于小细胞肺癌二线治疗的新型活性药物：一项针对难治性和敏感性疾病患者的II期研究。欧洲癌症早期临床研究和治疗组织和N
2. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. [J] . Smit EF, van Meerbeeck JP, Lianes P, Journal of Clinical Oncology . 2003,第21期

机译：两种基于顺铂的方案和紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的三臂随机研究：欧洲癌症肺癌研究与治疗组织（EORTC 08975）的III期临床试验。
3. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. [J] . Ichiki M, Gohara R, Rikimaru T, Chemotherapy: International Journal of Experimental and Clinical Chemotherapy . 2003,第4期

机译：将化疗与Irinotecan和Ifosfamide作为难治性或敏感的小细胞肺癌的二线治疗：II期研究。
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Anticancer activities of topotecan- genistein combination in prostate cancer cells [D] . Hormann, Vanessa P. 2012

机译：拓扑替康-金雀异黄素组合在前列腺癌细胞中的抗癌活性
6. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study [O] . V Georgoulias, A Agelidou, K Syrigos, 2005

机译：伊立替康联合顺铂与顺铂二线治疗接受紫杉烷类药物和吉西他滨治疗的晚期非小细胞肺癌患者的多中心随机II期研究
7. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975 [O] . SMIT EF, Van Meerbeeck Jan, LIANES P, 2003

机译：基于顺铂的两种方案和紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的三臂随机研究：欧洲癌症研究和治疗组织肺癌组织的III期临床试验 - EORTC 08975

European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer

著录项

相似文献

相关主题

期刊订阅